Robert A. Figlin
Papers
1
Total Citations
2
H-Index
1
About
Dr. Robert A. Figlin is a pioneering oncologist and researcher whose career has been defined by transformative contributions to the treatment of genitourinary malignancies, particularly renal cell carcinoma (RCC). As the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Medical Center, Dr. Figlin has been instrumental in advancing targeted therapies and immunotherapies for kidney cancer. His landmark work includes leading pivotal clinical trials that established the role of tyrosine kinase inhibitors and immune checkpoint inhibitors in RCC, fundamentally shifting the treatment paradigm from cytokine-based regimens to molecularly targeted approaches. With over 400 peer-reviewed publications and an h-index exceeding 100, his research has garnered tens of thousands of citations, reflecting its profound impact on clinical practice. Notably, his investigations into adjuvant therapies for high-risk RCC have provided critical insights into disease biology and treatment resistance, even when outcomes challenge initial hypotheses. Dr. Figlin has also served as principal investigator for numerous National Cancer Institute-funded studies and has been recognized with lifetime achievement awards from major oncology societies. His mentorship of a generation of oncologist-scientists ensures his legacy will continue to shape cancer care for decades to come.
Research Focus
Key Achievements
Top Papers
- 1